ClinicalTrials.gg
CompletedNCT03423979EVEREST-IUpdated Nov 26, 2025Results posted

Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter

A Phase 2 interventional study of Optilume™ BPH Prostatic DCB Dilation Catheter and Paclitaxel in Benign Prostatic Hyperplasia and Benign Prostatic Hypertrophy, sponsored by Urotronic Inc.. Completed at 5 sites in 2 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Urotronic Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Study summary

A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.

The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.

Read the detailed description

A prospective, non-randomized, multi-center study. The study will enroll up to 85 subjects to be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. Subjects will be followed up post-treatment at Foley removal, and up to 1 year. The subjects may choose to be followed-up annually for 5 years or until study close, whichever comes first.

Study device is Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System.

Study primarily outcomes are measured by 1). Change in IPSS score at 3-month post-procedure follow-up; 2). Major device or procedure related complications at 3-month post-procedure follow-up.

02

Conditions studied

  • Benign Prostatic Hyperplasia
  • Benign Prostatic Hypertrophy

Browse trials for

Keywords

  • BPH
03

In context

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's enrollment of 80 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Urotronic Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subject > 50 years of age who has moderate-to-severe LUTS (IPSS score of ≥ 13) and is a candidate for interventional therapy
  2. LUTS felt to be secondary to an enlarged prostate (henceforth termed LUTS/BPH)
  3. Peak urinary flow rate (Qmax) ≥ 5 mL/sec and ≤ 15 ml/sec with minimum voided volume of ≥ 125 ml
  4. Post-void residual (PVR) ≤ 250 ml
  5. Prostate volume 20 - 80 gm as determined by TRUS
  6. Prostatic urethra length is 35 - 55 mm as determined by TRUS
  7. Able to complete the study protocol in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  1. Interested in maintaining fertility and unwilling to use protected sex for the first 30 days post treatment
  2. Unwilling to abstain or use protected sex for ninety (90) days post treatment if sexual partner is of child bearing potential
  3. Presence of a penile implant or stent(s) in the urethra or prostate
  4. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
  5. PSA > 10 ng/ml unless prostate cancer is ruled out by . If PSA is > 4 ng/ml and ≤ 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the investigator via additional tests including digital rectal exam (DRE) and/or biopsy
  6. Confirmed or suspected of prostate or bladder
  7. Active or history of epididymitis within the past 3 months
  8. Previous pelvic irradiation or radical pelvic surgery
  9. Documented active urinary tract infection (UTI) by culture or bacterial prostatitis within last year documented by culture (UTI is defined as >100,000 colonies per ml urine from midstream clean catch or catheterization specimen)
  10. Visible hematuria with subject urine sample without known contributing factor
  11. Neurogenic bladder or sphincter abnormalities or neurological disorders that might affect bladder or sphincter function
  12. Previous or current diagnosis of urethral strictures, bladder neck contracture or detrusor muscle spasms
  13. Use of beta blockers, antihistamines, anticonvulsants, or antispasmodics within 1 week prior to treatment unless there is documented evidence of stable dosing for last 6 months (no dose changes)
  14. Use of alpha blockers, antidepressants, anticholinergics, androgens, daily tadalafil or gonadotropin-releasing hormonal analogs (prescribed for BPH) within 3 weeks prior to treatment
  15. Use of 5-alpha reductase inhibitor within 6 months prior to treatment
  16. Incidence of spontaneous urinary retention within 6 months prior to baseline assessment
  17. Post-void residual volume > 250 ml or catheter dependent bladder drainage
  18. Overactive bladder (OAB) or urge incontinence
  19. Known poor detrusor muscle function (e.g. Qmax \< 5 ml/sec)
  20. Current bladder stones or prostatic calculi
  21. Biopsy of prostate within 30 days prior to procedure or planned within 30 days following the procedure
  22. History of cancer in non-genitourinary system which is not considered cured (except basal cell or squamous cell carcinoma of the skin). A potential participant is considered cured if there has been no evidence of cancer within five years
  23. History of comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal [serum creatinine > 2.0 mg/dl], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or have a risk to subject per investigator's opinion
  24. Any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study quality of life questionnaires
  25. Expected \< one year
  26. Unable or unwilling to sign the Form (ICF) and/or comply with all the follow-up requirements
  27. Currently enrolled in or plan to enroll in another clinical trial for any disease except for observational only study
  28. In the opinion of the investigator, it is not in the subject's best interest to participate in the study
  29. Current treatment with anti-coagulants (e.g., warfarin or enoxaparin) or anti- medications other than aspirin (e.g., clopidogrel)
  30. Anatomy, e.g. presence of false passage or size of meatus, is not suitable for treatment in this study
  31. Device that corresponds with the subject's prostate size per the IFU is not available
  32. Intravesical prostatic protrusion (IPP) > 1 cm
  33. Current uncontrolled diabetes ( > 7%)
  34. Unable or unwilling to provide all the protocol-required semen samples
  35. Sensitivity to paclitaxel, on medication that may have negative interaction with paclitaxel, or for systemic paclitaxel
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Optilume™ BPH Prostatic DCB Dilation Catheter

    Optilume™ BPH Prostatic DCB treatment procedure

    Device: Optilume™ BPH Prostatic DCB Dilation Catheter · Drug: Paclitaxel

Interventions

  • DeviceOptilume™ BPH Prostatic DCB Dilation Catheter

    BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).

    Also known as: BPH Prostatic DCB

  • paclitaxel will release to adjacent tissue after the balloon inflated in the urethra

    Also known as: drug coated balloon

06

What researchers measure

Primary outcomes

  1. Therapeutic Responder at 3 Months

    The proportion of subjects experiencing at least a 40% improvement in International Prostate Symptom Score (IPSS) scores from baseline to 3 months. The IPSS contains the well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH symptoms. The first seven questions in the IPSS address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency, and scored on a 6-point scale (0 to 5). The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.

    Time frame: 90 days

  2. Major Device/Procedure Related Complications

    The proportion of subjects reporting a composite of device/procedure related severe urinary retention (lasting \>14 days), unresolved stress urinary incontinence, or bleeding requiring transfusion.

    Time frame: 90 days

07

Results

Posted Jul 3, 2023
Limitations and caveats
Interim review of safety data lead to refinement of device sizing and appropriate device size selection based on prostate dimensions for the final 30 subjects enrolled. Safety information reported for full cohort, as no pre-specified sub-analyses were planned.

Participant flow

Participant flow — Overall Study
MilestoneOptilume™ BPH Prostatic DCB Dilation Catheter
Started80
Completed52
Not completed28
Withdrew: Death5
Withdrew: Adverse event4
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up16

Outcome measures

PrimaryTherapeutic Responder at 3 Months

The proportion of subjects experiencing at least a 40% improvement in International Prostate Symptom Score (IPSS) scores from baseline to 3 months. The IPSS contains the well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH symptoms. The first seven questions in the IPSS address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency, and scored on a 6-point scale (0 to 5). The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.

Time frame:
90 days
Reported as:
Count of participants · Participants
Therapeutic Responder at 3 Months
ParticipantsOptilume™ BPH Prostatic DCB Dilation Catheter
Therapeutic Responder at 3 Months65
PrimaryMajor Device/Procedure Related Complications

The proportion of subjects reporting a composite of device/procedure related severe urinary retention (lasting \>14 days), unresolved stress urinary incontinence, or bleeding requiring transfusion.

Time frame:
90 days
Reported as:
Count of participants · Participants
Major Device/Procedure Related Complications
ParticipantsOptilume™ BPH Prostatic DCB Dilation Catheter
Major Device/Procedure Related Complications2

Adverse events

Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Optilume™ BPH Prostatic DCB Dilation Catheter5/80 (6.3%)25/80 (31.3%)50/80 (62.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventOptilume™ BPH Prostatic DCB Dilation Catheter
HematuriaRenal and urinary disorders8/80
Urethral StenosisRenal and urinary disorders4/80
Cerebrovascular AccidentNervous system disorders3/80
Urinary IncontinenceRenal and urinary disorders2/80
Complication of Device RemovalGeneral disorders2/80
Urinary RetentionRenal and urinary disorders1/80
Anesthetic Complication (Pulmonary)Injury, poisoning and procedural complications1/80
Stress Urinary IncontinenceRenal and urinary disorders1/80
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders1/80
Intestinal ObstructionGastrointestinal disorders1/80
Most frequent other events
Most frequent other events
EventOptilume™ BPH Prostatic DCB Dilation Catheter
HematuriaRenal and urinary disorders15/80
Urinary Tract InfectionInfections and infestations14/80
Urinary IncontinenceRenal and urinary disorders11/80
DysuriaRenal and urinary disorders10/80
Urinary RetentionRenal and urinary disorders9/80
Ejaculation DisorderReproductive system and breast disorders8/80

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Optilume™ BPH Prostatic DCB Dilation Catheter
Mean65.8 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Optilume™ BPH Prostatic DCB Dilation Catheter
Female0
Male80
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Optilume™ BPH Prostatic DCB Dilation Catheter
Race/Ethnicity — Black/African Origin10
Race/Ethnicity — Caucasian2
Race/Ethnicity — Hispanic/Latino68
Prostate Volume (g)
Prostate Volume (g)(grams)Optilume™ BPH Prostatic DCB Dilation Catheter
Mean35.9 ± 13.2
Presence of Intravesical Prostatic Protrusion
Presence of Intravesical Prostatic Protrusion(Participants)Optilume™ BPH Prostatic DCB Dilation Catheter
Count of participants10
08

Study locations

5 sites
  • Union Medica Hospital
    Santiago de los Caballeros, Santiago Province, Dominican Republic
  • Urolaser SRL
    Santo Domingo Oeste, Santo Domingo Province, Dominican Republic
  • Centro Medico Dr. Canela, SRL
    La Romana, Dominican Republic
  • Consultorios Royal Center
    Panama City, Urbanización Marbella Ciudad de Panamá, Panama
  • Centro Especializado San Fernando
    Panama City, Panama
09

References and documents

Publications

  • Pichardo M, Rijo E, Espino G, Lay RR, Estrella R, Gonzalez C, Fernandez M, Soriano D, Peralta IM, Kaplan SA. Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol. 2023 Aug;41(8):2209-2215. doi: 10.1007/s00345-023-04473-1. Epub 2023 Jun 24. PubMed 37354260 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2019, 17 months.

Results were first posted in Jul 2023, 4 years after primary completion.

Of 17 phase 2 interventional studies under Prostatic Hyperplasia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 6, 2018
StartActual
Dec 19, 2017
Primary completionActual
Jun 4, 2019
CompletionActual
May 25, 2024
Results first posted
Jul 3, 2023
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03423979
Lead sponsor
Urotronic Inc.
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Dec 19, 2017
Primary completion
Jun 4, 2019
Completion
May 25, 2024
Results posted
Jul 3, 2023
Last update
Nov 26, 2025

Study contacts

Jill Moland
study director · Urotronic Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion